Figure 5. Representative zymogram for MMP-2 and MMP-9 activity in cultures incubated under the treatments of bevacizumab or anti-CTGF antibody or simultaneous application of both antibodies. Conditioned media of cultures treated with 0.25, 0.5, and 0.8 mg/ml concentrations of bevacizumab, or 10 µg/ml anticonnective tissue growth factor (anti-CTGF), or bevacizumab (0.8 mg/ml) and anti-CTGF (10 µg/ml) collected, centrifuged, concentrated, and assessed with zymography. A and bars 1, 2, and 3 from F: Bevacizumab at applied concentrations increased matrix metalloproteinase-2 (MMP-2) activity in treated cultures compared with the control. B and bar 4 from F: Anti-CTGF decreased MMP-2 activity but (C and bar 5 from F) increased MMP-9 activity. D and bar 6 from F: MMP-2 activity remained unchanged with simultaneous application of bevacizumab and anti-CTGF. E: MMP-9 and bevacizumab comigrated on the zymography gel precluding comparisons of MMP-9 activity between the treated cells and the controls. Each column shows comparison of specified treated culture with control culture (% of control) and each bar represents the mean ± standard deviation (SD) of at least five independent experiments performed in duplicate (*p<0.05).